New cannabis green light lifts GW Pharma
GW Pharmaceuticals today saw its cannabis-based pain-relief medicine approved in another 10 European countries, sending its shares up nearly 2%
GW Pharmaceuticals today saw its cannabis-based pain-relief medicine approved in another 10 European countries, sending its shares up nearly 2%
Sativex, which is approved for use for MS sufferers and is being tested to see whether it could help cancer patients, is already on pharmacy shelves in the UK, Spain, Germany and Denmark, and being prepared for sale in Italy, Sweden, Austria and Czech Republic.
Now GW Pharma said it has received recommendation for approval in another 10 countries - Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia. Their launches are expected to start at the end of this year, after packaging wording is finalised in each country.
"Today's news means that regulatory authorities in a total of 18 European countries have now recommended Sativex for approval," Stephen Wright, GW's research and development director, said.
"The successful outcome of this most recent regulatory process provides further endorsement
of the quality, safety and efficacy of Sativex"
http://www.thisislondon.co.uk 08/05/2012
S
Soft Secrets
